State of Wisconsin Investment Board

The State of Wisconsin Investment Board (SWIB), established in 1951, is a state-owned investment manager based in Madison, Wisconsin. It primarily serves the Wisconsin Retirement System (WRS) and also manages accounts for the State Investment Fund (SIF) and other smaller state trust funds. SWIB invests globally across public equity, fixed income, and alternative investment markets, with a focus on the United States. Its investment portfolio is diversified, including allocations to real estate, private equity, and natural resources. SWIB employs a tactical asset allocation strategy, utilizing both in-house professionals and external money managers to make investment decisions based on extensive research and risk assessment. As a fiduciary, SWIB is required to make investment decisions solely for the benefit of its beneficiaries, adhering to the diligence, skill, and care expected of a prudent investor managing a large public pension fund.

Chris Eckerman

Senior Portfolio Manager and Head of Co-Investments and Senior Investment Officer, Private Equity Direct Investments

Anne-Marie Fink

Chief Investment Officer, Private Markets and Funds Alpha

Todd Mattina Ph.D

Chief Investment Officer and Head Economist, Asset and Risk Allocation

Past deals in Wisconsin

FluGen

Series A in 2017
FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

FluGen

Venture Round in 2016
FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

EatStreet

Series C in 2015
EatStreet, Inc. is an online and mobile food ordering service that connects customers with local restaurants across the United States. Founded in 2009 and headquartered in Madison, Wisconsin, the company caters primarily to college students and young professionals, offering a straightforward and affordable way to order delivery and takeout. The platform serves as a centralized hub, providing users with access to a comprehensive listing of partnered restaurants in their area, enabling quick and convenient food ordering. For restaurant owners, EatStreet offers a one-stop solution for online ordering and marketing, helping them attract new customers and increase sales. Through its web, mobile, and social products, EatStreet enhances the dining experience for consumers while supporting local businesses.

FluGen

Series A in 2015
FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

NeuWave Medical

Series C in 2015
NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Rentable

Venture Round in 2015
Rentable is an internet company founded in 2011 and based in Madison, Wisconsin, that focuses on enhancing the apartment rental search experience. Its web-based platform offers users a variety of tools, including localized flat listings, map-based searches, and shortlisting features, allowing for easy navigation through available properties. Additionally, Rentable provides an affordability calculator to assist users in determining suitable rental options based on their budget. By leveraging modern technology and an intuitive user interface, Rentable aims to streamline the process of finding apartments, making it more efficient and user-friendly for individuals seeking rental accommodations.

Zurex Pharma

Series B in 2014
Zurex Pharma, Inc. is a pharmaceutical and medical technology company based in Middleton, Wisconsin, focused on developing and commercializing antimicrobial products aimed at preventing healthcare-associated infections, particularly in surgical site wounds and catheter-related infections. The company’s product lineup includes ZuraPrep, a pre-surgical skin preparation designed to prevent surgical site infections; ZurAsept, an antimicrobial and antithrombotic solution for catheters that helps reduce catheter-related bloodstream infections; and ZuraGard, which protects against exit site wounds. Founded in 2008, Zurex Pharma operates as a subsidiary of Ash Access Technology, Inc., and is dedicated to addressing the challenges of infection control in healthcare settings.

Neurovance

Series A in 2014
Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

EatStreet

Series B in 2014
EatStreet, Inc. is an online and mobile food ordering service that connects customers with local restaurants across the United States. Founded in 2009 and headquartered in Madison, Wisconsin, the company caters primarily to college students and young professionals, offering a straightforward and affordable way to order delivery and takeout. The platform serves as a centralized hub, providing users with access to a comprehensive listing of partnered restaurants in their area, enabling quick and convenient food ordering. For restaurant owners, EatStreet offers a one-stop solution for online ordering and marketing, helping them attract new customers and increase sales. Through its web, mobile, and social products, EatStreet enhances the dining experience for consumers while supporting local businesses.

Montage

Series B in 2012
Montage is the single solution to engage, interview, and hire better candidates, faster. The company partners with many of the world’s most well-respected brands, including 100 of the Fortune 500, to create the high-tech, high-touch hiring experience the modern candidate expects. As the pioneer of purpose-built video interviewing, its proprietary technology integrates seamlessly with enterprise needs for reliability, scalability, compliance, and security. Montage is committed to market-driven innovation, incorporating applicable science, and data in its solutions to speed the process and improve the predictability of talent acquisition. Its commitment to superior client service and support is unique in the industry. The company helps each and every client at every stage of our partnership because we sincerely want them to succeed – and believe in building relationships for the long term. A privately held company, Montage is headquartered in Wisconsin.

Neurovance

Venture Round in 2012
Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

NeuWave Medical

Series B in 2012
NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Roche NimbleGen

Series D in 2003
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Roche NimbleGen

Series B in 2001
Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.